ClinicalTrials.gg
CompletedNCT03428594Updated Feb 9, 2018

CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis

A Phase 3 interventional study of CKD-11101 and NESP in Anemia of Chronic Kidney Disease, sponsored by Chong Kun Dang Pharmaceutical. Completed. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-02-09.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Jun 2015, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
403
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The aim of this study was to compare and evaluate efficacy and safety of intravenous CKD-11101 versus Darbepoetin alfa in patients who have renal anemia receiving hemodialysis.

Read the detailed description

This study was designed as randomized, double-blind, multi-center, Phase 3 clinical study to evaluate the efficacy and safety of intravenous CKD-11101 versus Darbepoetin alfa in patients who had renal anemia receiving hemodialysis.

The selection criteria are evaluated for 19-year-old patients who receive stable hemodialysis treatment for 3 months or more in patients with chronic renal failure. After completion of the stabilization period of 12 to 16 weeks for Darbepoetin Alfa, the subjects with the mean Hb levels of 10 to 12g/dl measured during the baseline visit and 0 week visit are randomized to the test and control groups in a 1:1 ratio during the randomization visit. They have a 20-week maintenance period and a 4-week evaluation period.

02

Conditions studied

  • Anemia of Chronic Kidney Disease

Browse trials for

03

In context

Anemia

1,810 studies on the registry are indexed under Anemia; 212 are open to participants now.

This study's enrollment of 403 is above the median of 117 across 1,336 interventional studies indexed under Anemia.

Browse Anemia studies →

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with 19 years of age or older

    1. Patients with anemia in chronic renal failure
    2. Patients who started hemodialysis more than 3 months ago and receive appropriate hemodialysis, satisfying the following criterion:

      -Kt/V is ≥ 1.2 or Urea reduction ratio is ≥ 65%

    3. Patients with the mean levels of 10 to 12g/dl measured at the baseline and randomization visits
    4. Patients with enough body iron stores who meet the following item:

      -Serum ferritin ≥ 100ng/ml or Transferrin saturation ≥ 20%

    5. Patients who have provided written consent to participate in the trial voluntarily

Exclusion criteria

  1. Patients with uncontrolled hypertension

    1. Patients who had to erythropoietin agents
    2. Patients who had known hypersensitivity to mammalian cell-derived products or diluting agents
    3. Patients with history of severe cardiovascular diseases
    4. Patients who have received red blood cell transfusion or hormone therapy for anemia correction within 12 weeks prior to randomization
    5. Patients whose anemia is not caused by chronic renal failure or may affect anemia correction
    6. Patients whose /ALT test results performed at screening exceed twice of normal upper limit
    7. Patients who had experience of positive result in anti-erythropoietin antibody in previous treatment with erythropoiesis stimulating agent
    8. Patients who have been planned to change the dialysis method
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
403 participants (actual)

Study arms

  • Experimental
    CKD-11101

    The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.

    Biological: CKD-11101

  • Active comparator
    NESP

    The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.

    Biological: NESP

Interventions

06

What researchers measure

Primary outcomes

  1. Changed amount of mean hemoglobin level in evaluation period compared to the baseline

    The equivalence test on mean hemoglobin level of test drug and to Reference Drug administration groups in evaluation period (Weeks 20 - 24) compared to the baseline (Weeks -4 - 0) will be conducted.

    Time frame: ([Mean of hemoglobin level measured in Weeks 20 - 24] - [Mean of hemoglobin level measured at Weeks -4 - 0])

  2. Mean administration dose in evaluation period: Mean dose administered in Weeks 20 - 24

    The equivalence test on mean administration dose of test drug and to Reference Drug administration groups in evaluation period (Weeks 20 - 24) will be conducted.

    Time frame: Weeks 20 - 24

Secondary outcomes

  1. Ratio of subjects who achieve target level of hemoglobin during the evaluation period

    Ratio of subjects who maintain target level of hemoglobin: Compare the number of subjects who do not deviate from target level of hemoglobin during the evaluation period between groups

    Time frame: Weeks 20 - 24

  2. Mean hemoglobin levels at Weeks 20 and 24

    Mean hemoglobin level at Weeks 20 and 24: Compare mean hemoglobin level at Weeks 20 and 24 between groups

    Time frame: Weeks 20, 24

  3. Ratio of subjects who maintain hemoglobin level ≥ 10g/dl during maintenance period and evaluation period (interval of every 2 weeks)

    Compare ratio of subjects who maintain hemoglobin level ≥ 10g/dl during maintenance period and evaluation period between groups (interval of every 2 weeks)

    Time frame: Weeks 0 - 24

  4. Ratio of subjects who changed dose during maintenance period and evaluation period

    Ratio of subjects who changed dose: Compare ratio of subjects who change dose during maintenance period and evaluation period between groups

    Time frame: Weeks 0 - 24

  5. Ratio of subjects who receive transfusion during maintenance period and evaluation period

    Ratio of subjects who receive red blood cell transfusion: Compare ratio of subjects who receive red blood cell transfusion during maintenance period and evaluation period between groups

    Time frame: Weeks 0 - 24

  6. Number of red blood cell transfusion per subject during maintenance period and evaluation period

    Number of red blood cell transfusion per subject: Compare number of red blood cell transfusion per subject during maintenance period and evaluation period between groups

    Time frame: Weeks 0 - 24

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Jun 2017, 24 months.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 50. This study's 24 months is close to that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2018
First posted
Feb 9, 2018
StartActual
Jun 2015
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Last update
Feb 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03428594
Responsible party
Sponsor
First posted
Feb 9, 2018
Start date
Jun 2015
Primary completion
Jun 2017
Completion
Jun 2017
Last update
Feb 9, 2018

Study contacts

Su-Kil Park, M.D.,Ph.D.
principal investigator · Asan Medical Center, College of Medicine, Univ. of Ulsan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CKD-11101

Start the discussion